CHECKIT
John Wilson
CEO
We have worked with Yellowstone Advisory for a number of years and they transformed our investor relations strategy which significantly increased the interest of our business to both institutional and retail investors. We have been impressed by their understanding of the smaller companies market and their results focussed approach to IR. I would recommend their services without hesitation.
EQUINITI
Guy Wakeley
CEO
Yellowstone Advisory provided valuable input into the interim results announcement and presentation, helping to ensure the investment messaging was consistent throughout the documents. Great relationships and credibility with investors enables them to solicit useful feedback which we have used in developing our future investor messaging.
.png){kind=small}
Oxford Cannabinoid Technologies plc Webinar
Thu, 10 Jun
|Webinar
Oxford Cannabinoid Technologies is pleased to announce that the Company's management team will conduct a live presentation to retail investors introducing the company following their recent admission to the London Stock Exchange and presenting the outlook for the year ahead.
Time & Location
10 Jun 2021, 13:00
Webinar
About the event
Oxford Cannabinoid Technologies Holdings plc (“OCT”) is a UK-based next generation cannabis pharmaceutical company focussed on the development cannabinoid-based prescription medicines to target indications in the £42.5bn pain market, with regulatory marketing approval from agencies including the FDA, EMA and MHRA. Established in 2017, OCT aims to become a global leader in developing licensed prescription medicines that target the endocannabinoid system to address significant unmet medical needs. To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines. Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed four rounds of investment.